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Abstract
Purpose The aim of this study is to evaluate the long-term
outcome of patients with locally advanced breast cancer
treated with neoadjuvant systemic chemotherapy (NST) in
routine clinical practice.
Methods Four hundred and nine patients were identiWed
between January 1999 and December 2011. All patients
received NST followed by surgery, adjuvant treatments and
radiotherapy, as appropriate.
Results At Kaplan–Meier analysis, patients with surgical
stage III disease were more likely to develop distant metas-
tasis and die from breast cancer (p < 0.001). Luminal A and
luminal B/HER2-negative patients had better prognosis;
moreover, patients with hormone receptor (HR)-positive
tumors had a signiWcantly longer DRFS (p < 0.0049) and
OS (p < 0.0001) compared with patients with HR-negative
tumors as well as patients who underwent breast-conserving
surgery (DRFS and OS: p < 0.001). In multivariate analy-
sis, HR negativity (p < 0.001 for both DRFS and OS), mas-
tectomy (DRFS: p = 0.009; OS: p = 0.05) and stage III
disease (DRFS: p < 0.001; OS: p = 0.003) were associated
with shorter DRFS and OS.
Conclusions HR negativity, mastectomy and pathological
stage III disease are the variables independently associated
with a worse outcome in our cohort of patients. These data
are of high interest since they derive from a very heteroge-
neous group of patients, treated with diVerent neoadjuvant/
adjuvant regimens outside of clinical trials and with a long
follow-up period.
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Neoadjuvant systemic therapy (NST) has been used in
locally advanced breast cancer in order to convert a previ-
ously unresectable cancer into an operable one (Hortobagyi
et al. 1988; Danforth et al. 1990; Schwartz et al. 1994).
More recently, it has been widely administered in primarily
operable breast cancer to reduce tumor volume and allow
conservative surgery (Fisher et al. 1997; van der Hage et al.
2001; Semiglazov et al. 2011). The downstaging of the pri-
mary tumor and the increase in breast conservation rates
seems to be the only clinical beneWt of NST, given that sev-
eral studies failed to demonstrate an improvement of over-
all survival compared with postoperative adjuvant
chemotherapy (Fisher et al. 1997, 1998; Bear et al. 2006;
Mauri et al. 2005). Breast cancer is a heterogeneous disease
that varies widely in response to standard therapies and out-
comes (Rouzier et al. 2005). In this perspective, NST repre-
sents an opportunity to determine the intrinsic resistance/
sensitiveness of breast cancer to chemotherapy. Moreover,
the extent of residual disease in the breast and axillary sur-
gical specimens after NST, classiWed according to the
revised 2003 American Joint Committee on Cancer (AJCC)
tumor-node-metastasis (TNM) staging system, has been
reported to be associated with relapse and survival (Carey
et al. 2005). Pathologic complete response (pCR) achieved
after NST, when deWned as non-invasive and non-in situ
cancer in breast and nodes, is predictive of good prognosis
and might be used as surrogate of survival (Kuerer et al.
1999; Kaufmann et al. 2006). However, patients with hor-
mone receptors (HR)-positive tumors usually have low
rates of pCR and maintain a good long-term outcome even
in the presence of residual disease (no pCR) (Colleoni et al.
2009; Huober et al. 2010; Precht et al. 2010; Straver et al.
2010; Kim et al. 2010). In this group of patients, pCR fails
to predict survival, emphasizing the importance of tumor
biology rather than response to neoadjuvant chemotherapy
as a prognostic marker in some subtypes of breast cancers
(von Minckwitz et al. 2012).
The aim of this study is to evaluate the long-term out-
come in a series of patients with locally advanced breast
cancer consecutively treated with NST in our institution.
All patients came from the routine clinical practice and
were not included in clinical trials.
Patients and methods
Patient population
This is a single institution study. The charts of all patients
with locally advanced breast cancer, performance status
0–2 (ECOG scale), consecutively treated with NST at the
Medical Oncology Division, University of Chieti Hospital
between January 1999 and December 2011, were reviewed
for this retrospective study. Four hundred and nine patients
were identiWed. In all cases, diagnosis of invasive breast
cancer was established by tru-cut biopsy of the primary
tumor. Patients with bilateral and inXammatory breast can-
cer were excluded.
All patients received preoperative chemotherapy and
those with HR-positive tumor received adjuvant hormonal
therapy for 5 years. Chemotherapy regimens administered
included: CMF (Xuorouracil, methotrexate and cyclophos-
phamide); single-agent epirubicin; EC (epirubicin and
cyclophosphamide); FEC (Xuorouracil, epirubicin and
cyclophosphamide); E-CMF (single-agent epirubicin fol-
lowed by CMF); single-agent taxanes; ET (epirubicin and
taxol); EC-T (EC followed by docetaxel); EC-TAXEL (EC
followed by docetaxel and capecitabine) and other combi-
nations including platinum compounds, vinorelbine and
pegylated doxorubicin. Ninety-nine patients received adju-
vant tamoxifen, 125 postmenopausal patients received aro-
matase inhibitors (anastrozole or letrozole) and 71 patients
tamoxifen followed by exemestane. Ninety-four patients
treated after 2005 and carrying HER2-positive tumors
received Trastuzumab simultaneously with neoadjuvant
chemotherapy and/or postoperatively to complete 1 year of
treatment.
Surgical procedures consisted of mastectomy or breast-
conserving surgery (BCS). Sentinel node biopsy after NST
was performed in 54 patients; axillary lymph node dissec-
tion was performed in 371 (90.1 %) patients, including 16
having positive sentinel nodes. Adjuvant breast radiother-
apy was delivered to patients who underwent BCS as well
as to patients who underwent mastectomy but had initial
stage cT3, cN2 or cN3 disease.
Pathological assessments
Estrogen (ER)/progesterone receptors (PR) and human epi-
dermal growth factor type 2 receptor (HER2) were deter-
mined on pretreatment biopsy and on surgical specimens by
immunohistochemistry. HR status was considered positive
if ¸10 % of tumor cells stained for ER and/or PR. HER2
status was assessed by HercepTest (Dako Italia, Milan,
Italy). Samples were scored as follows: score 0, membrane
staining in ·10 % of tumor cells; score 1+ , partial and/or
faint membrane staining in >10 % of tumor cells; score 2+,
weak to moderate, complete membrane staining in >10 %
tumor cells and score 3+, strong, complete membrane stain-
ing in >10 % of tumor cells. FISH or CISH was carried out
on all tumors with HercepTest 2+. Tumors with a score of
3+ by immunohistochemistry (IHC) or gene ampliWcation
by FISH were considered as HER2 positive. Immunohisto-
chemical detection of Ki-67 was performed using the MIB-1123
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according to the Nottingham grading system (Elston and
Ellis 1991).
We could not exactly deWne breast cancer intrinsic sub-
types with immunohistochemistry in all tumors (Goldhirsch
et al. 2011), since Ki-67 assessment was not available in
172 (42.0 %) samples. So we classiWed tumors as follows:
(1) luminal A and luminal B/HER2 negative; (2) luminal
B/HER2 positive; (3) HER2 enriched; (4) triple negative
(Houssami et al. 2012).
pCR was deWned as non-invasive cancer within the
breast (ypT0/is) and lymph node (ypN0), also classiWed as
Stage 0 (Kuerer et al. 1999; Kaufmann et al. 2010). Patho-
logical stages were categorized according to the American
Joint Committee on Cancer Staging Manual, 7th ed. (Edge
et al. 2010).
Locoregional recurrence (LRR) was deWned as any chest
wall recurrence in those who underwent mastectomy, any
ipsilateral in-breast recurrence in those achieving breast
conservation and any recurrence in the axillary, supracla-
vicular or internal mammary nodes.
Data collection
Medical records for all patients were reviewed retrospec-
tively and the cut oV date for follow-up set on December
31, 2011. Clinical and pathological characteristics for each
patient were entered on an anonymized database. Since
patients’ enrollment began in 1999, complete information
was not available for all 409 patients; thus, denominators
may vary throughout the article. The follow-up contacts
were carried out at 6-month intervals over the Wrst 5 years,
and at 12-month intervals thereafter.
Study endpoints and statistics
The primary endpoint of this study was overall survival
(OS), deWned as the interval between the time of surgery
and the date of death from any cause or censoring. Survi-
vors were censored at the date of last contact. The second-
ary endpoints were rate of pCR and distant relapse—free
survival (DRFS), deWned as the time from breast surgery to
the Wrst occurrence of distant metastasis or intercurrent
deaths without distant recurrence.
A two-sided level of signiWcance of 0.05 was applied to
all statistical tests. In univariate analysis, the relationships
between patients/tumor characteristics and pCR were
assessed by Pearson’s 2 or Fisher’s exact test, as appropri-
ate. A stepwise multivariate logistic regression was used to
identify independent predictors of pCR among baseline
patients/tumor characteristics. Survival curves were derived
from Kaplan–Meier estimates and compared by log-rank
test and hazard ratio (HR) (Massarweh et al. 2006). A mul-
tivariate Cox proportional hazard model was carried out to
assess the relative inXuence of prognostic factors on sur-
vival (De Placido et al. 2003). All statistical analyses were
performed using the SPSS Statistic software version 19
(IBM, Armonk, New York).
Results
Baseline patient and tumor characteristics
Clinical and pathological baseline characteristics of
patients are shown in Table 1. The median age was
48.8 years (range 25–80), with 20 (4.9 %) patients being
younger than 35 years and 15 (3.7 %) older than 70 years.
Clinical tumor size was ¸3 cm in 175 (42.8 %) patients;
346 (84.6 %) patients had ductal carcinoma. Tumor grade
was 1–2 in 289 (70.7 %) and grade 3 in 87 (21.2 %)
patients. Ki-67 was available in 237 (58 %) cases and was
>14 % in 135 (56.9 %). Tumors were classiWed in four
molecular subtypes according to the tumor staining for ER/
PR and HER2 status: 211 (51.9 %) were HER2 negative,
luminal A or luminal B (ER and/or PR positive); 84
(20.6 %) were HER2 positive, luminal B (ER and/or PR
positive); 53 (13.0 %) were HER2 enriched (ER and PR
negative, HER2 positive); 59 (14.5 %) were triple negative
(ER and PR negatives, HER2 negative). Most patients, 237
(58.0 %), received chemotherapy based on anthracycline
and taxanes. Among 137 women with HER2-positive
tumor, 43 (31.4 %), diagnosed before 2005, were not
treated with Trastuzumab, 29 (21.2 %) received adjuvant
Trastuzumab and 65 (47.4 %) received neoadjuvant and
adjuvant Trastuzumab. A total of 300 (73.3 %) patients
received more than four cycles of chemotherapy.
Relationship between baseline characteristics and pCR
In the univariate analysis, pCR was signiWcantly associated
with tumor grade, proliferative activity, molecular subtype,
type of NST and number of chemotherapy cycles (Table 1),
patients with the worst prognostic factors having the best
pCR rates. In the multivariate analysis, only HR-negative
tumors, independently from HER2 status (HER2 enriched:
p = 0.043; triple negative: p = 0.002) and the use of neoad-
juvant Trastuzumab (p = 0.035) were signiWcantly associ-
ated with higher pCR rates (Table 2).
Patients’ characteristics after NST
Patients’ characteristics after completion of NST are
reported in Table 3. BCS was performed in 241 (58.9 %)
patients and mastectomy in the remaining 168 (41.1 %).
Absence of cancer in the breast (ypT0) was found in 75123
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(ypN0) in 181 (44.2 %) patients and a total of 61 (14.9 %)
patients had a pCR, that is, absence of invasive cancer both
in breast and nodes. Most patients received adjuvant treat-
ments: 125 (30.6 %) patients had only hormonal therapy,
54 (13.2 %) only chemotherapy, 105 (25.6 %) chemother-
apy followed by hormonal therapy and 94 (23.0 %)
received adjuvant Trastuzumab either alone (33 patients),
with hormonal therapy (39 patients), with chemotherapy
(11 patients) or with chemotherapy and hormonal therapy
(11 patients). Adjuvant radiotherapy was delivered to 310
(75.8 %) patients, including 101 patients who underwent
mastectomy.
Survival
Median follow-up was 42.1 months (range 0.8–
147.3 months). During follow-up, 25 (6.1 %) patients had
local relapse, 84 (20.5 %) had distant metastases and 53
(13.0 %) died. We evaluated patients’ outcome in relation
to diVerent variables such as pCR, stage at surgery, tumor
molecular subtype, use of Trastuzumab for HER2-positive
tumors, type of surgery and breast radiotherapy. The occur-
rence of local relapse was not correlated with stage of dis-
ease at surgery, type of surgery and radiation therapy, while
it was more frequent among patients with HR-negative
tumors (p = 0.007 by Pearson’s 2).
At Kaplan–Meier analysis of the whole population, pCR
was not found to be a prognostic factor for DRFS and OS
(not shown). However, excluding from the analyses
Table 1 Association of baseline factors and pCR in univariate analysis
* 10.2 % pCR in patients treated with chemotherapy only
a Unknown were not included in univariate analysis
No. (%) pCR no. (%) p value
Age
Median age 48.8 years 
(range 25–80 years)
·35 years 20 (4.9) 5 (25.0)
>35 years 389 (95.1) 56 (14.4) n.s.
Clinical T
·3 cm 213 (52.1) 30 (14.0)
¸3 cm 175 (42.8) 30 (17.1)
Unknowna 21 (5.1) 1 (4.8) n.s.
Histologic type
Ductal 346 (84.6) 51 (14.7)
Lobular 57 (14.0) 10 (17.5)
Others 6 (1.4) 0 n.s.
Grade
1–2 289 (70.7) 25 (8.6)
3 87 (21.2) 19 (21.8)
Unknowna 33 (8.1) 17 (51.5) 0.001
Ki-67
·14 % 102 (43.1) 4 (3.9)
>14 % 135 (56.9) 33 (22.2)
Unknowna 172 (50.0) 24 (14.0) 0.000
Molecular subtype
Luminal A & B/HER2 negative 211 (51.9) 12 (5.7)
Luminal B/HER2 positive 84 (20.6) 14 (16.6)
HER2 enriched 53 (13.0) 18 (33.9)
Triple negative 59 (14.5) 17 (28.8)
Unknowna 2 (0.04) 0.000
Type of NST
Various 107 (26.1) 5 (4.5)*
Anthracycline and taxane 237 (58.0) 30 (12.6)*
Chemotherapy + Trastuzumab 65 (15.9) 26 (40.0) 0.000
No. of chemotherapy cycles
·4 109 (26.7) 7 (6.4)
>4 300 (73.3) 54 (18.0) 0.004
Table 2 Association of baseline factors and pCR in multivariate analysis
Odds ratio 95 % CI p value
Age
>35 years Reference
·35 years 2.081 0.426–10.175 n.s.
Clinical T
·3 cm Reference
¸3 cm 1.040 0.414–2.611 n.s.
Histologic type
Other Reference
Ductal 2.965 0.327–6.424 n.s.
Lobular 5.995 0.213–10.785 n.s.
Grade
1–2 Reference
3 1.275 0.418–3.885 n.s.
Ki-67
·14 % Reference
>14 % 3.689 0.899–15.132 n.s.
Molecular subtype
Luminal A and B/HER2 negative Reference
Luminal B/HER2 positive 1.564 0.252–9.716 n.s.
HER2 enriched 6.090 1.062–34.921 0.043
Triple negative 10.646 2.307–40.125 0.002
Type of NST
Various 2.290 Reference n.s.
Anthracycline and taxane 11.334 0.300–17.419 0.035
Chemotherapy + Trastuzumab 1.182–108.719
No. of chemotherapy cycles
·4 2.158 Reference n.s.
>4 0.308–15.143123
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tumors (a group of patients with favorable outcome, repre-
senting 51.9 % of the entire study population), pCR
resulted predictive of better DRFS (p = 0.028: HR = 0.37,
95 % CI = 0.19–0.72) with a trend toward signiWcance for
OS (p = 0.06; HR = 0.34, 95 % CI = 0.16–0.77) (Fig. 1a,
b). Patients with higher stage of disease after NST were
more likely to develop distant metastasis and die from
breast cancer (Fig. 2a, b; p < 0.001). Patients who achieved
pCR (stage 0) had DRFS and OS rates of 87.1 % (95 % CI:
77.3–96.9 %) and 92.0 % (95 % CI: 84.8–99.2 %), respec-
tively, similar to those of patients with surgical stage I
(DRFS: 85.9 %; 95 % CI: 77.1–94.7 % and OS: 80.4 %;
95 % CI: 66.9–93.9 %). Stage II patients had DRFS rates of
61.3 % (95 % CI: 39.7–82.9 %) and OS rates of 76.8 %
(95 % CI: 55.2–98.4 %), while stage III patients had DRFS
rates of 48.5 % (95 % CI: 35.4–61.6 %) and OS rates of
44.6 % (95 % CI: 17.7–71.5 %).
SigniWcant diVerences in DRFS (p = 0.006) and OS
(p = 0.006) were observed among patients with diVerent
tumor molecular subtypes (Fig. 3a, b), the group of patients
with luminal A or luminal B/HER2-negative tumors show-
ing a better prognosis. Moreover, patients with HR-positive
tumors had a signiWcant longer DRFS (p < 0.005:
HR = 0.54, 95 % CI = 0.35–0.85) and OS (p < 0.0001:
HR = 0.34, 95 % CI = 0.19–0.63) compared with patients
with HR-negative tumors (Fig. 3c, d). When survival analy-
sis was stratiWed according to HER2 status, the DRFS and
OS advantage for HR-positive tumors was limited to the
HER2-negative population (p = 0.016: HR = 0.50, 95 %
CI = 0.25–0.97 and p < 0.0001: HR = 0.25, 95 % CI = 0.11–
0.60, respectively) (Fig. 3e, f), while among HER2-posi-
tive group, HR positivity was predictive of a longer
DRFS (p = 0.044: HR = 0.50, 95 % CI = 0.24–1.0), but
not OS (not shown). In our population, neither HER2 sta-
tus nor the use of Trastuzumab in the HER2-positive
patients was statistically associated with clinical out-
come (not shown).
Patients who underwent BCS were more likely to have a
better DRFS (p < 0.0001: HR = 0.36, 95 % CI = 0.23–0.55)
and OS (p = 0.0014: HR = 0.42, 95 % CI = 0.24–0.72)
compared with those who required mastectomy (Fig. 4a, b).
No diVerences in survival were observed in patients treated
with or without radiotherapy after surgery (not shown).
In multivariate analysis, the variables independently
associated with shorter DRFS and OS were absence of HR
expression (DRFS and OS: p < 0.001), mastectomy (DRFS:
p = 0.009; OS: p = 0.05) and stage III disease (DRFS:
p < 0.001; OS: p = 0.003), whereas the molecular subtype
luminal B/HER2-positive tumors reached statistical signiW-
cance for OS (p = 0.035), but not for DRFS (Tables 4, 5).
Discussion
In this retrospective study, we show that HR negativity,
requirement for mastectomy and pathological stage III dis-
ease are independently associated with a worse outcome in
breast cancer patients treated with NST in clinical practice.
These data are of high interest since they derive from a very
heterogeneous group of patients, treated with diVerent neo-
adjuvant/adjuvant regimens outside of clinical trials and
with a long follow-up period.
During the course of the last 12 years, the adjuvant treat-
ment of patients aVected by early breast cancer is pro-
foundly changed, going from Wrst generation regimens like
CMF and epirubicin–CMF, second generation regimens
like FEC to third generation regimens, like EC followed by
docetaxel (Sachelarie et al. 2006; Peto et al. 2012). Also,
we delivered Trastuzumab in the adjuvant treatment of
HER2-positive tumors from 2005 and in the neoadjuvant
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2012). Finally, surrogate deWnitions of intrinsic subtypes
with immunohistochemistry have only recently proven to
be eVective in deWning prognosis and selecting adjuvant
therapy in early stage breast cancer patients (Cheang et al.
2009; Nielsen et al. 2010; Goldhirsch et al. 2011).
In our study, high tumor grade, high proliferative activ-
ity, HR-negativity expression in tumor biopsy, the use of
neoadjuvant Trastuzumab and an increase in number of
chemotherapy cycles resulted signiWcantly associated with
higher rates of pCR at univariate analysis, consistent with
current literature (Colleoni et al. 2009; Huober et al. 2010;
Kim et al. 2010; Precht et al. 2010; Straver et al. 2010;
Untch et al. 2011; von Minckwitz et al. 2011), but only HR
negativity and neoadjuvant Trastuzumab were conWrmed at
multivariate analysis. The association between HR negativ-
ity and pCR has been observed also in a recently published
meta-analysis based on 20 studies providing data with clas-
siWcation of HER2 positivity according to HR status
(Houssami et al. 2012). Their estimates of pCR were 8.3 %
in the luminal A and luminal B/HER2-negative subtype;
18.7 % in the luminal B/HER2-positive subtype; 38.9 % in
the HER2-enriched subtype and 31.1 % in the triple nega-
tive subtype (Houssami et al. 2012).
However, although most neoadjuvant chemotherapy
trials have shown that pCR is associated with a favorable
outcome in terms of DRFS and OS (Kuerer et al. 1999;
Kaufmann et al. 2006; Buzdar et al. 2007; Dawood et al.
2008), in our cohort pCR was not predictive of better
prognosis. This discordance is not explained by the deWni-
tion of pCR we applied, since it is now the most com-
monly used. DiVerent deWnitions for pCR have been used
in diVerent clinical trials, varying according to site (i.e.,
breast only or both breast and axillary) and residual dis-
Fig. 1 a Distant relapse free survival (DRFS) and b overall survival (OS) stratiWed by pathological complete response (pCR) for the whole popu-
lation, excluding patients with HR-positive/HER2-negative tumors
Fig. 2 a Distant relapse free survival (DRFS) and b overall survival (OS) stratiWed by pathological stage after systemic neoadjuvant chemotherapy123
J Cancer Res Clin Oncol (2013) 139:269–280 275ease (i.e., presence of focal invasive cancer, non-invasive
cancer residuals or absence of invasive and non-invasive
cancer) (SataloV et al. 1995; Bear et al. 2003; Green et al.
2005; von Minckwitz et al. 2010). Absence of invasive
and non-invasive cancer has been reported to be associ-
ated with a better prognosis (von Minckwitz et al. 2010).
The incidence of residual non-invasive cancer in our
study (only six patients had residual in situ ductal carci-
noma in the Wnal pathologic examination), is too low to
justify the poorer outcome observed in the whole popula-
tion. More importantly, most of the patients in the study
(211 patients, 51.9 %) had luminal A or luminal B/HER2-
Fig. 3 a, c, e Distant relapse free survival (DRFS) and b, d, f overall
survival (OS) stratiWed by molecular subtypes for the whole popula-
tion (a, b), by hormone receptor (HR) status (HR+ and HR¡) for the
whole population (c, d) and by HR status for patients with HER2-neg-
ative tumors (e, f)123
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proliferating and less chemotherapy responsive tumors. In
these patients, pCR has been shown to be not associated
with prognosis (von Minckwitz et al. 2010). The high
number of patients included in the luminal A or luminal
B/HER2-negative subgroup in our study could have
diluted the eVect of pCR on outcome. Indeed, when these
patients were excluded from the analyses, pCR was sig-
niWcantly associated with longer DRFS and OS.
The outcome of patients included in this study was sig-
niWcantly aVected by stage at surgery, HR expression and
type of surgery. Several studies have showed that a higher
stage after NST is predictive of poor prognosis (Fisher et al.
1998; Cance et al. 2002; Carey et al. 2005). Consistently,
we found that patients with stage III disease had a signiW-
cantly shorter DRFS and OS. Lack of HR expression is
another well-established parameter associated with poor
prognosis (Osborne and McGuire 1979; McGuire et al.
1986). In our study, after a follow-up of about 12 years,
patients with HR-negative tumors had a signiWcantly lower
rate of DRFS (61 vs. 67 %, p < 0.001) and OS (56.6 vs.
65.5 %, p < 0.001) compared with patients with HR-posi-
tive tumors, independently from HER2 status, at least for
DRFS. The OS advantage for HR positivity was lost in the
subgroup of HER2-positive tumors. This might be
explained by the lower responsiveness of HR- and HER2-
Fig. 4 a Distant relapse free survival (DRFS) and b overall survival (OS) stratiWed by type of surgery. BCS breast conservative surgery
Table 4 Multivariable 
proportional hazard regression 
model predicting DRFS
Parameter estimate Hazard ratio 95 % CI p value
Age
>35 years Reference
·35 years 0.158 1.171 0.457–3.003 n.s.
Histologic type
Lobular Reference n.s.
Ductal 0.065 1.067 0.568–2.006 n.s.
Others 0.187 1.206 0.247–5.874
Molecular subtype preNST
Luminal A and B/HER2 negative Reference
Luminal B/HER2 positive 0.591 1.807 0.970–3.365 0.062
HER2 enriched 1.678 5.354 2.747–10.435 0.000
Triple negative 1.141 3.130 1.703–5.752 0.000
Type of surgery
BCS Reference
Mastectomy 0.643 1.903 1.170–3.093 0.009
Stage
0 Reference
I 0.185 1.203 0.419–3.454 n.s.
II 0.751 2.119 0.825–5.443 n.s.
III 1.810 6.108 2.376–15.707 0.000123
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(De Placido et al. 2003; Massarweh et al. 2006).
BCS was carried out in 241 (58.9 %) patients and this is
in agreement with the percentage of BCS performed after
NST reported in clinical trials (Bear et al. 2006; Fisher
et al. 1998; Alm El-Din and Taghian 2009). These patients
had a signiWcantly better prognosis in terms of DRFS and
OS compared with patients who underwent mastectomy.
Similar data are presented by other authors who related
these Wndings to patients’ selection: patients were more
likely to have BCS if they presented with earlier stage dis-
ease or a clinical complete or greater than 50 % partial
response (Schwartz et al. 1994; Kuerer et al. 1999). In our
cohort, this advantage was independent of age, histologic
type, molecular subtype and surgical stage, but we agree
that the achievement of BCS can be considered as an indi-
rect measure of clinical response of the primary tumor,
parameter not included in our multivariate analyses since
we could not uniformly assess it throughout our patient
population. In this study, clinical response was evaluated
before, during and after neoadjuvant chemotherapy either
by physical examination or by echographic and mammo-
graphic measurements, but the lack of standardization did
not allow us to include clinical response as a variable for
the multivariate analyses. Considering achievement of BCS
as a surrogate marker of primary tumor response, our
results suggest that the clinical response to NST is a strong
predictive factor of good outcome. Some neoadjuvant trials
have provided evidence of the prognostic value of clinical
response, even when it was not correlated with pCR (Hort-
obagyi et al. 1988; Jacquillat et al. 1991; Cameron et al.
1997; Pierga et al. 2003).
During follow-up, 25 (6.1 %) patients had LRR, which
was related neither to the type of surgery nor to radiother-
apy. These data are in agreement with those of other
authors reporting a rate of LRR ranging from 6 to 10 %,
with a trend toward higher rates in patients with basal-like
subtypes (Chen et al. 2004; Tanioka et al. 2010; Meyers
et al. 2011; Min et al. 2011).
In conclusion, this retrospective neoadjuvant study,
based on a population of patients treated in the practice of
clinical medicine, shows that HR negativity, stage III dis-
ease at surgery and failure to achieve BCS after NST are
independent factors negatively associated with prognosis.
Moreover, the results of this study further conWrm that pCR
is of no prognostic value in patients with luminal A or lumi-
nal B/HER2-negative tumors. These patients, therefore,
should not be included in neoadjuvant clinical trials whose
primary end point is pCR, as suggested by other authors
(Eiermann et al. 2001; Berruti et al. 2011).
Acknowledgments Supported by the Consorzio Interuniversitario
Nazionale per Bio-Oncologia (CINBO) and by the Gruppo Interdisci-
plinare Cure Oncologiche (GICO), Asl Lanciano-Vasto-Chieti. The
authors are grateful to Mrs. Camille St. Pierre for careful reviewing of
the manuscript.
ConXict of interest None of the authors has any potential Wnancial
conXict of interest related to this manuscript.
Table 5 Multivariable 
proportional hazard regression 
model predicting OS
Parameter estimate Hazard ratio 95 % CI p value
Age
>35 years Reference n.s.
·35 years 0.178 1.195 0.404–3.533
Histologic type
Lobular Reference
Ductal 0.424 1.528 0.590–3.955 n.s.
Others 0.509 1.664 0.170–16.266 n.s.
Molecular subtype preNST
Luminal A and B/HER2 negative Reference
Luminal B/HER2 positive 0.846 2.330 1.062–5.111 0.035
HER2 enriched 1.751 5.761 2.438–13.610 0.000
Triple negative 1.696 5.453 2.620–11.350 0.000
Type of surgery
BCS Reference
Mastectomy 0.606 1.834 1.170–3.093 0.056
Stage
0 Reference
I 0.726 2.066 0.547–7.808 n.s.
II 0.466 1.593 0.409–6.205 n.s.
III 1.900 6.683 1.877–23.801 0.003123
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